|1.||Matsuda, Kazuko: 2 articles (10/2015 - 12/2012)|
|2.||Iwaki, Yuichi: 2 articles (10/2015 - 12/2012)|
|3.||Makhay, Malath: 2 articles (10/2015 - 12/2012)|
|4.||Kawarabayashi, Tatsuhiko: 2 articles (06/2009 - 02/2006)|
|5.||O'Brien, Geoffrey: 1 article (10/2015)|
|6.||Lovato, Luis M: 1 article (10/2015)|
|7.||House, Stacey L: 1 article (10/2015)|
|8.||Lewis, Lawrence M: 1 article (10/2015)|
|9.||Ferguson, Ian: 1 article (10/2015)|
|10.||Antoniu, Sabina: 1 article (08/2014)|
|1.||Asthma (Bronchial Asthma)
10/01/2015 - "The goal of this study was to evaluate the safety and efficacy of intravenous bedoradrine (MN-221), a highly selective β2-adrenergic agonist, as adjunct to standard therapy in the management of patients with acute exacerbation of asthma who did not respond to standard therapy. "
12/01/2012 - "Study MN-221-CL-005 assessed the safety profile and preliminary efficacy of MN-221 in patients with stable moderate-to-severe asthma when given as a fixed dose over 1- or 2- hr infusion. "
12/01/2012 - "Trial MN-221-CL-004 assessed the safety profile and preliminary efficacy of MN-221 in escalating doses in patients with stable mild-to-moderate asthma. "
08/01/2014 - "The intravenous use of bedoradrine has demonstrated promising preliminary efficacy in existing clinical trials for exacerbated asthma. "
12/01/2012 - "Evaluation of bedoradrine sulfate (MN-221), a novel, highly selective beta2-adrenergic receptor agonist for the treatment of asthma via intravenous infusion."
|2.||Chronic Obstructive Pulmonary Disease (COPD)
08/01/2014 - "However, the efficacy of bedoradrine is still uncertain in exacerbated COPD. "
08/01/2014 - "This drug evaluation paper reviews the potential therapeutic agent bedoradrine, an ultraselective β2 agonist, which is currently under development for treating exacerbated asthma and COPD. "
08/01/2014 - "Bedoradrine for treating asthma and chronic obstructive pulmonary disease."
|3.||Dyspnea (Shortness of Breath)
10/01/2015 - "Intravenous bedoradrine, in addition to standard therapy, did not significantly increase %FEV1 at 3 h, but it was associated with significantly improved dyspnea scores. "
10/01/2015 - "The dyspnea scores were significantly improved for patients treated with bedoradrine compared to placebo (AUC0-2 hP < 0.005, AUC0-3 hP < 0.05). "
|4.||Premature Obstetric Labor (Premature Labor)
06/01/2009 - "Bedoradrine is a promising drug for the treatment of preterm labor in obstetrical practice because it has better selectivity for beta(2)-AR and specificity for the uterus than currently used agents and may effectively delay spontaneous delivery."
02/01/2006 - "KUR-1246 is a promising drug for the treatment of preterm labor in obstetric practice because it is as efficacious as currently used agents yet less likely to produce direct effects on the fetus."
|2.||Adrenergic Agonists (Adrenergic Receptor Agonist)